Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 8, 2010, Pages 1749-1752

  Jacqueline, Cédric ^a   Amador, Gilles ^a   Caillon, Jocelyne ^a   Le Mabecque, Virginie ^a   Batard, Eric ^a   Miègeville, Anne Françoise ^a   Biek, Donald ^b   Ge, Yigong ^b   Potel, Gilles ^a   Hamel, Antoine ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b Cerexa Inc   (United States)

Author keywords

Bone; Linezolid; MRSA; Vancomycin

Indexed keywords

CEFTAROLINE; LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; OXAZOLIDINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BONE INFECTION; BONE MARROW; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; RABBIT; SYNOVIAL FLUID; ANIMAL; BONE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BONE AND BONES; BONE MARROW; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; OXAZOLIDINONES; RABBITS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 77954724135     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq193     Document Type: Article

References (21)

1. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336: 999-1007.
2. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
3. Iizawa Y, Nagai J, Ishikawa T et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10: 146-56.
4. Sader HS, Fritsche TR, Kaniga K et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005; 49: 3501-12.
5. Villegas-Estrada A, Lee M, Hesek D et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP2a by two anti-MRSA β-lactam antibiotics. J Am Chem Soc 2008; 130: 9212-3.
6. Jacqueline C, Navas D, Batard E et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 45-51.
7. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
8. Jacqueline C, Batard E, Perez L et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 2002; 46: 3706-11.
9. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus: comparison with linezolid and vancomycin in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51: 3397-400.
10. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
11. Amador G, Gautier H, Le Mabecque V et al. In vivo assessment of the antimicrobial activity of a calcium-deficient apatite vancomycin drug delivery system in a methicillin-resistant Staphylococcus aureus rabbit osteomyelitis model. Antimicrob Agents Chemother 2010; 54: 950-2.
12. Yin LY, Lazzarini L, Li F et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005; 350: 1670-3.
13. Rouse MS, Piper KE, Jacobson M et al. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006; 57: 301-5.
14. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
15. Asseray N, Jacqueline C, Le Mabecque V et al. Activity of glycopeptides against S. aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy. Antimicrob Agents Chemother 2005; 49: 857-9.
16. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
17. Rana B, Butcher I, Grigoris P et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50: 747-50.
18. Kutscha-Lissberg F, Hebler U, Muhr G et al. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47: 3964-6.
19. Metallidis S, Nikolaidis J, Lazaraki G et al. Penetration of linezolid into sternal bone of patients undergoing cardiopulmonary bypass surgery. Int J Antimicrob Agents 2007; 29: 742-4.
20. Talbot GH, Thye D, Das A et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51: 3612-6.
21. Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: 300-11.